In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis, ...
Please provide your email address to receive an email when new articles are posted on . Dupilumab is approved for atopic dermatitis in children aged 6 months and older. Patients on dupilumab did not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback